new therapeutic tools, urged to introduce the concept of "early rheumatoid arthritis" (eRA). Although the length of "early" [ranging from 3 months to 3 years according to the different studies (3)], has not yet been precisely defined, conversely there is general consensus that the goal of early arthritis management is remission and prevention ofjoint destruction Conventional radiography only visualizes the late changes in RA joints, while there is evidence for high-field Magnetic Resonance Imaging (MRI) being highly sensitive and able to accurately reveal joint alteration not yet identified by X-ray (4) . Furthermore, several studies have confirmed the direct relationship between early inflammatory joint alterations (i.e. synovitis, bone oedema) and subsequent erosions, all evaluated with MRI (5) .
Anti TNF-u agents represent the most effective available therapy in patients with RA (6) . Etanercept (Etn -recombinant fully human protein composed of an immunoglobulin linked to two p75 TNF soluble receptors) has been shown to be safe and effective in RA, by reducing disease activity and limiting progressive joint damage. It has been approved as monotherapy as well as in association with Methotrexate (Mtx) for RA treatment (7) .
The aim of this preliminary study is to analyse the Etn + Mtx effectiveness in inducing clinical and MRI remission in active poor-prognosis eRA patients after a one-year treatment period. Moreover, the possibility to maintain total remission after Etn interruption has also been explored.
MATERIALS AND METHODS
Twenty patients with active (disease activity score on 44 joints [DAS 44 ] > 3.7), poor-prognosis [a total score 2: 6 at the Visser et al (8) predictive criteria for erosive persistent arthritis, either anti-citrullinatedcyclic-peptide (CCP) antibodies or MRI erosions], eRA (::;24 months) fulfilling the ACR criteria (9), naive for anti TNF-(l therapy, were considered eligible for this prospective 2-year follow-up study. Exclusion criteria were: age < 18 years, disease duration > 24 months and any type of common contraindications (i.e. malignancies, demyelinating disorders, pregnancy, etc.) to receiving anti-TNF-(l therapy. All patients were recruited among those attending our outpatient clinic, in concordance with the ethical guidelines of the 1975Declaration of Helsinki, as declared in a prior approval by the Institution's human research committee.
Images of hands and wrists were carried out using a whole body high-field MRI 1.5-T superconductive magnet (Siemens) equipped with a 20 em circular surface coil. Patients were placed in prone position with the arm extended and the hand in the centre of the coil. Coronal, axial and sagittal images were obtained by using fat suppressed T'I-weighted spin-echo sequences, before and after i.v. injection of 0.1 mmol/kg gadopentate dimeglumine, with a gradient echo and stir technique. Images were scored for synovitis, bone oedema and erosions according to the Outcome Measures in Rheumatology Clinical Trials (OMERACT) definitions (10) .
Patients received Etn 25 mg twice weekly plus Mtx 15 mg weekly. DAS44' Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), and RF (rheumatoid factor) were performed every six months; MRI of hands and wrists were carried out at baseline (TO), 12 months (Tl) and 24 months (T2). At baseline radiography, anti-CCP antibodies and Visser score were also assessed. RF was measured by nephelometry. The Eular remission threshold (DAS 44 < 1.6) was used as clinical remission (11), whereas a synovitis score c 3 associated with a total score::; 6 was arbitrarily considered as imaging remission. Patients who reached clinical and imaging remission at Tl, were considered eligible for interrupting biological therapy.
Statistical analysis
Statistical analysis was performed with nonparametric testing for data not normally distributed, using the STATA 8.2 software. Within each group, the results were prospectively analysed (weeks 22 and 54 between them and versus baseline) using Wilcoxon's signed-ranks test. The statistical significance of the difference between groups of data was carried out by Mann-Whitney test for independent data; p values ::;0.05 were considered statistically significant.
RESULTS
Baseline demographic, clinical and imaging of the 20 patients are resumed in Table I .
At Tl 8/20 (40%) of patients reached clinical and imaging remission, thus Etn was interrupted in this group of patients (Group A), whereas it was continued in the remaining ones (Group B). There were no significant differences regarding demographic, clinical and MRI scores between the two groups at baseline (Table II) .
Group B showed a significant (p< 0.05) reduction in the DAS 44 at Tl, followed by a further values are expressed as mean ± standard deviation ns = not significant not significant decrease at T2. Group A showed a significant decrease in the DAS 44 at T1 (p< 0.02); 1 year after Etn interruption (T2) the clinical condition did not change, as reflected by the DAS44 that remains almost stable (Table II , Fig. 1 ). A significant decrease in mean CRP (p < 0.02) and ESR (p < 0.001) values was observed in the overall patients at T1, with a further, not significant, reduction in mean CRP at T2 (data not shown).
Imaging findings
At baseline, radiography showed joint damage (erosions or juxtarticular osteoporosis) in only 4/20 (20%) patients, the total amount of detected erosions being 8 in 4 patients. MRI was instead able to identify joint damage in all the patients; the total amount of detected erosions was in fact 76 (60 micro-erosions) in 19 patients, whereas all the patients presented synovitis alone or with bone oedema (Table I) .
At T1, a significant reduction in synovitis, bone oedema and total score (p<O.O I) was observed both in group A and group B. In particular, a synovitis resolution in 4 patients, bone oedema resolution in all the patients and the healing of 9 micro-erosions in 3 patients were documented in Group A (Table  II , Figs. 2 and 4) . Group B exhibited a synovitis resolution in one patient, bone oedema resolution in all the patients and the healing of 15 microerosions in 4 patients, with two patients presenting new micro-erosions. At T2 a further not significant decrease in synovitis and total score was observed in this group (Table II, Fig. 2 ).
After 1 year from Etn interruption (T2) group A showed an increase in all the MRI scores that was significant for the synovitis and total score; all the patients presented a new appearance or a marked worsening of synovitis, bone oedema appeared again in two patients, and 5 patients presented 12 new micro-erosions ( Figs. 2 and 4) . A significant difference between the groups was observed for the synovitis and total score both at T1 and T2 (p < 0.05), with group A and group B showing the better values at T1 and T2 respectively (Table II, Fig. 2 ).
DISCUSSION
This study indicates the possibility to induce clinical and imaging remission in a relevant percentage of patients with eRA through the early adoption of Etn + Mtx therapy, and reports that MRI is able to detect ongoing articular damage even in clinically silent patients.
All the patients showed a significant decrease of disease activity at T1 with 40% of them reaching both clinical and imaging remission (group A). Furthermore, group A patients showed a sustained clinical remission one year after Etn suspension (T2) with the disease activity remaining apparently silent.
On the contrary, a relevant worsening of joint damage was assessed by MRI at T2 in this group of patients with a boosted synovitis, bone oedema and erosions as reflected by the significant increase in the synovitis and total Omeract scores.
The current trend is to start TNF-alpha blockers in RA patients in a very narrow (:S 6 months) window of opportunity from diagnosis, to obtain maximum effect, by reducing inflammation and maintaining functional ability. In this way, several groups considered the clinical impact ofdifferent therapeutic strategies in eRA. Klareskog (12) ; other authors studied the effectiveness of very early treatment with Infliximab + Mtx in active eRA (4, 13) . More recently Paul Emery in reporting the l-year results of the COmbination of Mtx and Etn in active early rheumatoid arthritis Trial (COMET) has highlighted the importance of early intervention to achieve clinical remission, by showing that 50% of the patients reached clinical remission after 52 weeks of treatment (14) .
In the current preliminary study, the same combination treatment has allowed to reach both clinical and imaging remission by 40% of the patients after a l-year therapy period with a significant reduction of the DAS44, bone oedema, synovitis and total MRI scores. Group B patients showed a further, although not significant, clinical and MRI improvement at T2, whereas group A showed stable clinical condition but a substantial structural worsening, thus revealing a strong dissociation between clinical and imaging outcome after Etn suspension.
The advantages of MRI compared to traditional radiography are well-documented. MRI is able, in fact, to assess soft tissue structures, early joint damage (i.e. synovitis) and pre-erosive changes (i.e, bone oedema) (15) (16) . Thus MRI should be considered an important tool for early RA diagnosis, being more sensitive than conventional X-ray for detection of early inflammatory and destructive changes in RAjoints (4) . In this study MRI was able to show structural progression despite the absence of clinical inflammatory activity, demonstrating that RA may still be active and aggressive also in this apparently silent condition. Similar discrepancies between clinical and imaging findings has been reported by other authors (17) (18) . Recently Brown et al. (19) , on a large cohort of RA patients in clinical remission treated with conventional DMARDs, found structural damage in 63%, 89% and 96% of the patients by using radiography, ultrasonography (US) and MRI respectively, thus reporting the importance of imaging sensitive assessment to evaluate disease status and define true remission.
The current preliminary study confirms the inaccuracy of the traditional clinical measures of RA disease activity (DAS 44 ) to predict imaging status and may represent a step forward, considering that, to our knowledge, dissociation between clinical remission and ongoing structural inflammation has not yet been described after biological therapy interruption.
In conclusion, this study describes the possibility to induce clinical and imaging remission in eRA patients treated with Etn + Mtx and indicates that anti TNF-a interruption leads to structural relapses also in the absence of clinical activity, suggesting to take care in biological therapy withdrawal to avoid future clinical disability.
The results here presented are strictly interwoven with Pharmacoeconomic considerations, such as the increase of direct costs, linked to the difficulty in interrupting TNF-alpha blockers, as well as the growing role ofthe new sensitive imaging techniques in the early diagnosis and monitoring, versus the delay/reduction of disability. It would be wise to plan studies in this field, considering the current relative lack of information. Moreover, ethical considerations on the possible use of these available tools, which have been demonstrated as making a difference in the quality of management of RA patients, should also be taken into account.
